Nippon Shinyaku sets up China subsidiary

Mid-sized Japanese drugmaker Nippon Shinyaku (TYO: 4516), which is focussed on rare disease and blood cancer treatments, has announced the setting up a subsidiary in China’s capital, Beijing.

The subsidiary, which is called Beijing Ai Nu Ai Shi, will act as a marketing authorization holder (MAH) to bring Nippon Shinyaku's drugs to China.

The Japanese pharma in June filed a new drug application (NDA) in China for Viltepso (viltolarsen), a treatment for the rare disease Duchenne muscular dystrophy. The company already has a trading office in Beijing, but only an MAH is allowed to conduct necessary practices such as filing IND applications in China, according to Chinese regulations.